

AVEO PHARMACEUTICALS INC  
Form 8-K  
June 04, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 30, 2012

**AVEO Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction

of Incorporation)

**001-34655**  
(Commission

File Number)

**04-3581650**  
(IRS Employer

Identification No.)

Edgar Filing: AVEO PHARMACEUTICALS INC - Form 8-K

**75 Sidney Street**

**Cambridge, Massachusetts**  
(Address of Principal Executive Offices)

**Registrant's telephone number, including area code: (617) 299-5000**

**02139**  
(Zip Code)

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

At the annual meeting of shareholders of AVEO Pharmaceuticals, Inc. (the Company) held on May 30, 2012, the Company's shareholders voted on the following proposals:

1. The following nominees were elected to the Company's Board of Directors for terms expiring at the 2013 annual meeting of shareholders.

	For	Withheld	Broker Non-Votes
Mr. Kenneth Bate	33,585,100	150,035	4,356,839
Dr. Ronald DePinho	33,623,051	112,084	4,356,839
Dr. Anthony Evnin	33,708,223	26,912	4,356,839
Mr. Tuan Ha-Ngoc	33,670,381	64,754	4,356,839
Dr. Raju Kucherlapati	33,662,626	72,509	4,356,839
Mr. Henri Termeer	33,579,070	156,065	4,356,839
Mr. Kenneth Weg	19,084,041	14,651,094	4,356,839
Dr. Robert Young	33,707,123	28,012	4,356,839

2. A non-binding, advisory proposal on the compensation of the Company's named executive officers was approved.

For:	33,471,047
Against:	256,138
Abstain:	7,950
Broker Non-Votes:	4,356,839

3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2012 was ratified.

For:	37,919,378
Against:	160,724
Abstain:	11,872

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AVEO Pharmaceuticals, Inc.**

Date: June 4, 2012

By: /s/ David B. Johnston  
David B. Johnston

Chief Financial Officer